Objective-Endothelin-1 is a potent vasoconstrictor derived from vascular endothelium. Elevated endothelin-1 levels are observed in a host of cardiovascular pathologies including cardiomyopathy. The epigenetic mechanism responsible for endothelin-1 induction in these pathological processes remains elusive. Approach and Results-We report here that induction of endothelin-1 expression in endothelial cells by angiotensin II (Ang II) was accompanied by the accumulation of histone H3K4 trimethylation, a preeminent histone modification for transcriptional activation, on the endothelin-1 promoter. In the meantime, Ang II stimulated the expression and the occupancy of Suv, Ez, and Trithorax domain 1 (SET1), a mammalian histone H3K4 trimethyltransferase, on the endothelin-1 promoter, both in vitro and in vivo. SET1 was recruited to the endothelin-1 promoter by activating protein 1 (c-Jun/c-Fos) and synergized with activating protein 1 to activate endothelin-1 transcription in response to Ang II treatment. Knockdown of SET1 in endothelial cells blocked Ang II-induced endothelin-1 synthesis and abrogated hypertrophy of cultured cardiomyocyte. Finally, endothelial-specific depletion of SET1 in mice attenuated Ang II-induced pathological hypertrophy and cardiac fibrosis. Conclusions-Our data suggest that SET1 epigenetically activates endothelin-1 transcription in endothelial cells, thereby contributing to Ang II-induced cardiac hypertrophy. As such, screening of small-molecule compound that inhibits SET1 activity will likely offer a new therapeutic solution to the treatment of cardiomyopathy. (Arterioscler Thromb Vasc Biol.
T he vascular endothelium plays an important role maintaining the homeostasis of the cardiovascular system. 1 By producing and releasing a range of vasoactive substances, the endothelium helps safeguard the normal functions of the heart and other key organs. Therefore, imbalanced synthesis of endothelium-derived vasoactive substances disrupts the physiological rhythm of the vessels and is invariably associated with such cardiovascular pathologies such as hypertension, atherosclerosis, and cardiac hypertrophy. 2 Endothelin-1 is by far the most potent vasoconstrictor produced by vascular endothelial cells. 3 In addition to its role in tuning the vascular tone, endothelin-1 also regulates inflammation, 4 generation of reactive oxygen species, 5 cell proliferation and migration, 6 extracellular matrix deposition, 7 and hyperplasia/hypertrophy. 8 Mounting evidence suggests that many stress signals inflict insult on the cardiovascular system by targeting endothelin-1 expression in endothelial cells. For instance, chronic inflammation, induced by several proinflammatory cytokines including IL-1β, IFN-γ, and tumor necrosis factor-α, has been documented to upregulate endothelin-1 transcription via the transcription factor NF-κB 9 . Angiotensin II (Ang II) activates endothelin-1 transcription via c-Jun/cFos while Ang II-induced cardiac hypertrophy and fibrosis is attenuated in endothelial-specific endothelin-1 knockout mice. 10, 11 A better delineation of the underpinnings that contribute to the regulation of endothelin-1 transcription in endothelial cells would yield novel therapeutic solutions to protect the integrity of the cardiovascular system.
It has been increasingly recognized that epigenetic gene regulation actively participates in the pathogenesis of cardiovascular diseases. [12] [13] [14] [15] Among the different branches of the mammalian epigenetic machinery, histone-modifying enzymes regulate transcription by influencing the chromatin structure. It is generally thought that certain histone modifications, such as acetylated histones H3 and H4 and trimethylated H3 lysine 4 (H3K4Me3), are associated with an open chromatin structure and transcriptional activation. 16 In contrast, methylated H3K9 and H3K27 are synonymous with a compact chromatin structure and therefore transcriptional repression. 17 Suv, Ez, and Trithorax domain 1 (SET1) is the core component of the mammalian H3K4 methyltransferase complex (complex protein associated with SET1, or COMPASS); cells deficient in SET1 lose virtually all H3K4Me3 marks. 18 To date, it remains enigmatic whether SET1 is involved in the regulation of endothelin-1 expression.
In the present study, we tackled the role of SET1 in Ang II-induced endothelin-1 transactivation and pathological hypertrophy. Our data suggest that SET1 can be activated by Ang II in vascular endothelial cells and is essential for Ang II-mediated endothelin-1 induction. Specific targeting of SET1 in endothelial cells alleviates cardiac hypertrophy and fibrosis in mouse models. Therefore, screening of smallmolecule compound that inhibits SET1 activity will likely aid the development of novel interventional strategies against cardiomyopathy.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Induction of Endothelin-1 Transcription by Ang II Is Accompanied by Signature Histone Marks
To explore the potential involvement of histone-modifying enzymes in Ang II-induced endothelin-1 expression in endothelial cells, we performed the following experiments. Immortalized human umbilical vein endothelial cells (EAhy926) or primary human pulmonary endothelial cells were treated with Ang II (100 nmol/L) and harvested at different time points to measure endothelin-1 mRNA levels and the enrichment of modified histones surrounding the endothelin-1 promoter regions. As expected, Ang II treatment led to an induction of endothelin-1 messages as early as 12 hours after exposure in both EAhy926 cells ( Figure 1A ) and human pulmonary endothelial cells ( Figure 1C ). In the meantime, modified histones that are synonymous with transcriptional activation, including acetylated histone H3 (AcH3), acetylated histone H4 (AcH4), and trimethylated histone H3K4 (H3K4Me3) started to accumulate on the proximal endothelin-1 promoter, but not on the distal endothelin-1 promoter ( Figure 1B and 1D) . We also performed similar experiments in a mouse model of Ang II-induced pathological hypertrophy. Chronic infusion of Ang II for 4 weeks resulted in robust induction of endothelin-1 messages in the lungs ( Figure 1E ).
Concomitantly, enrichment of H3K4Me3 on the endothelin-1 promoter was increased in the lungs of mice receiving Ang II infusion relative to those receiving saline infusion ( Figure 1F ). In comparison, H3K4Me3 levels did not change on the GAPDH promoter. Taken together, these data suggest that Ang II-induced endothelin-1 transcription is accompanied by an open chromatin structure as evidence by the accumulation of active histone marks.
SET1 Is Activated by Ang II in Endothelial Cells
SET1 is the catalytic component of the COMPASS complex that specializes in histone H3K4 trimethylation. 19 To evaluate whether SET1 could be activated by Ang II and contribute to the induction of endothelin-1 transcription, we first examined SET1 expression in endothelial cells in response to Ang II stimulation. Treatment of Ang II increased mRNA ( Figure 2A ) and protein ( Figure 2B ) levels of SET1 in EAhy926 cells peaking at 24 hours after the addition of Ang II. More importantly, Ang II also promoted the binding of SET1 to the endothelin-1 proximal promoter as evidenced by chromatin immunoprecipitation assay ( Figure 2C ). Similar observations were made in human pulmonary endothelial cells ( Figure 2D-2F ). We also measured the expression and binding activity of SET1 in mouse lungs. In mice with pathological hypertrophy, mRNA ( Figure 2G ) and protein ( Figure 2H ) levels of SET1 were significantly increased in the lungs when compared with the control mice. Finally, chromatin immunoprecipitation assay revealed that there was more SET1 binding on the endothelin-1 promoter in the lungs of mice infusion with Ang II than in the lungs of mice infused with saline ( Figure 2I ).
Next, we tackled the question whether SET1 mediates endothelin-1 transactivation by Ang II in cultured endothelial cells. Overexpression of SET1 enhanced endothelin-1 promoter activity in the presence of Ang II in a dose-dependent manner ( Figure 3A) . In contrast, small-interfering RNA targeting SET1 attenuated Ang II-induced endothelin-1 transactivation ( Figure 3B ). Depletion of SET1 ( Figure I1A and I1B in the online-only Data Supplement for knockdown efficiency) also abrogated the induction of endothelin-1 mRNA and protein levels by Ang II in both EAhy926 cells ( Figure 3C ) and human pulmonary endothelial cells ( Figure 3D ). Paralleling a reduction of endothelin-1 expression in the absence of SET1, the accumulation of H3K4Me3 on the endothelin-1 promoter after Ang II treatment was suppressed ( Figure 3E and 3F) . Collectively, these data indicate that Ang II can activate SET1 both in vitro and in vivo and that SET1 is essential for Ang II-induced endothelin-1 expression in cultured vascular endothelial cells likely through influencing H3K4Me3 levels on the endothelin-1 promoter.
SET1 Is Recruited to the Endothelin-1 Promoter by Activating Protein 1
Hong et al 11 have previously reported that activating protein 1 (AP-1), a heterodimer composed of c-Jun and c-Fos, binds to the proximal endothelin-1 promoter and is indispensible for Ang II-induced endothelin-1 transcription. Because epigenetic factors are recruited to the chromatin by sequence-specific transcription factors, 20 we asked whether AP-1 could be responsible for SET1 recruitment in response to Ang II stimulation. Coimmunoprecipitation assay showed that there was an interaction between SET1 and c-Jun/c-Fos in endothelial cells ( Figure 4A ). In addition, Ang II treatment promoted the formation of a SET1/AP-1 complex on the endothelin-1 promoter but not on the GAPDH promoter ( Figure 4B ), indicating that the interaction between SET1 and AP-1 was specific. In further support of our hypothesis that AP-1 is responsible for SET1 recruitment, we silenced c-Jun/c-Fos expression in and harvested at indicated time points. SET1 expression was examined by quantitative polymerase chain reaction (qPCR; A) and Western (B). SET1 protein levels were normalized by β-actin levels and presented as relative protein expression. C, SET1 occupancy surrounding the ET-1 promoter region was measured by chromatin immunoprecipitation (ChIP) assay. D-F, human pulmonary endothelial cells were treated with Ang II (100 nmol/L) and harvested at indicated time points. SET1 expression was examined by qPCR (D) and Western (E). SET1 protein levels were normalized by β-actin levels and presented as relative protein expression. F, SET1 occupancy surrounding the ET-1 promoter region was measured by ChIP assay. G-I, C57/BL6 mice were induced to develop cardiac hypertrophy as described Materials and Methods in the online-only Data Supplement. SET1 expression in the lungs was examined by qPCR (G) and Western (H). I, SET1 occupancy surrounding the ET-1 promoter region was measured by ChIP assay using lung lysates.
c-Fos ( Figure 4E ) to activate the endothelin-1 promoter in endothelial cells. On the contrary, when the AP-1 binding site was mutated, SET1 could no longer activate its transcription ( Figure  IIB in the online-only Data Supplement). Therefore, SET1 relies on AP-1 for its recruitment to the endothelin-1 promoter and synergizes with AP-1 to activate endothelin-1 transcription.
Endothelial SET1 Is Necessary for Ang II-Induced Cardiomyocyte Hypertrophy In Vitro
Next, we sought to put the role of SET1 in Ang II-induced endothelin-1 transactivation in endothelial cells in the context of pathological hypertrophy. To this end, we collected the media from endothelial cells after various treatments and then A, An ET-1 promoter luciferase construct was transfected into EAhy926 cells with increasing doses of SET1 in the presence or absence of Ang II (0.1 μmol/L). SET1 overexpression and Ang II treatment synergistically activated ET-1 promoter transcription. B, An ET-1 promoter luciferase construct was transfected into EAhy926 cells with indicated siRNAs followed by treatment with Ang II (0.1 μmol/L). C and D, EAhy926 cells (C) and human pulmonary endothelial cells (HPECs; D) were transfected with indicated small interfering RNAs followed by treatment with Ang II (0.1 μmol/L). ET-1 levels were measured by quantitative polymerase chain reaction (qPCR) and ELISA. E and F, EAhy926 cells (E) and HPECs (F) were transfected with indicated siRNAs followed by treatment with Ang II (0.1 μmol/L). Chromatin immunoprecipitation assay was performed with anti-histone H3K4 trimethylation (H3K4Me3). SET1 depletion erased H3K4 methylation form the ET-1 promoter. SCR indicates scrambled siRNA.
used the conditioned media to treat cardiomyocyte. As shown in Figure 5A , conditioned media from Ang II-treated endothelial cells elicited an upregulation of several hypertrophic markers in H9C2 cells, when compared with media collected from mock-treated endothelial cells. When SET1 was silenced in endothelial cells before Ang II treatment, conditioned media were no longer able to induce pro-hypertrophic marker genes in H9C2 cells. Similar observations were made when we used primary neonatal right ventricular myocyte ( Figure 5B ). To verify whether this Ang II-stimulated, endothelium-derived, and SET1-dependent prohypertrophic signal was indeed endothelin-1, we pretreated cardiomyocytes with a specific endothelin-1 receptor antagonist (bosentan): bosentan pretreatment effectively abrogated the response of cardiomyocyte to the conditioned media whether in the presence or absence of SET1. Therefore, we conclude that SET1 is essential for Ang II-induced cardiomyocyte hypertrophy probably through its regulation of endothelin-1 expression in endothelial cells.
Endothelial SET1 Is Necessary for Ang II-Induced Cardiomyocyte Hypertrophy In Vivo
Finally, we evaluated our working model that endothelial SET1 is necessary for Ang II-induced cardiomyocyte hypertrophy in vivo. C57/BL6 mice were induced to develop cardiac hypertrophy by subcutaneous Ang II infusion. In the meantime, SET1 was silenced by lentiviral delivery of an endothelial-specific vector carrying interfering RNA targeting SET1 as have been shown for other proteins previously. 13, 14, 21 Immunofluorescence staining suggested that SET1 expression was specifically suppressed in the vascular endothelium ( Figure IIIA a reduction in endothelin-1 mRNA ( Figure 6A ) and protein ( Figure 6B ) levels in Ang II-infused mice. Consequently, there was a decrease of H3K4Me3 levels on the endothelin-1 promoter in the lungs ( Figure 6C ). Thus, we have again validated the role of endothelial SET1 in Ang II-induced endothelin-1 transactivation in a mouse model of pathological hypertrophy.
Next, we assessed cardiac functions of mice with endothelial-specific depletion of SET1. Cardiac hypertrophy was significantly alleviated in mice infected with SET1 interfering RNA, as indicated by gross appearances (Figure 7A ), heart weight versus body weight, or heart weight corrected by tibia length (Figure 7B ), measurements of left ventricular end-systolic dimension ( Figure 7C ) and left ventricular posterior wall dimension ( Figure 7D ), when compared with mice infected with scrambled interfering RNA. Attenuation of cardiac hypertrophy was also evidenced by wheat germ agglutinin staining of cardiomyocyte ( Figure IIIC with endothelial-specific SET1 silencing. These observations, however, were not paralleled by changes in blood pressure: whereas Ang II infusion elevated systolic pressure and mean arterial pressure in mice, neither of which was significantly altered by SET1 depletion, suggesting that the beneficial effects after SET1 silencing cannot be interpreted as secondary to blood pressure normalization ( Figure IIIF SET1) is necessary for pressure-overload-induced cardiomyocyte hypertrophy in vivo. A-J, C57/BL6 mice were induced to develop cardiac hypertrophy by subcutaneous angiotensin II (Ang II) infusion. Lentivirus carrying endothelial-specific short hairpin RNA targeting SET1 were injected via tail vein. A, Gross morphology of heart. B, Heart weight (HW) vs body weight (BW) and HW vs tibia length (TL). C and D, Left ventricular end-systolic dimension (LVsd) and left ventricular posterior wall dimension (LVPWd) were measured as described in Materials and Methods in the online-only Data Supplement. E and F, Fraction shortening (FS) and ejection fraction (EF) were measured by ultrasound. G, Expression of hypertrophic marker genes was examined by quantitative polymerase chain reaction (qPCR). Cardiac fibrosis was evaluated by qPCR (H), Western blotting (I), and picrosirius red staining (J). n=8-10 mice for each group. K and L, C57/BL6 mice were induced to develop cardiac hypertrophy by the transverse aortic constriction (TAC) procedure. Lentivirus carrying endothelial-specific short hairpin RNA targeting SET1 were injected via tail vein. K, ET-1 expression in the lungs was examined by qPCR and ELISA, respectively. n=5 mice for each group. L, HW vs BW and HW versus TL were measured. n=8 mice for each group. M, A model depicting endothelial-SET1 mediates Ang II-induced cardiac hypertrophy through transactivating ET-1 gene expression. ANP indicates atrial natriuretic peptide; BNP, brain natriuretic peptide; and SCR, scrambled siRNA.
endothelium-dependent/endothelium-independent relaxations (Figure IIIH in the online-only Data Supplement). In conclusion, endothelial-selected depletion of SET1 helps antagonize cardiac hypertrophy and fibrosis after chronic Ang II infusion.
To extrapolate our findings to a broader context, we examined the role of endothelial SET1 in pathological hypertrophy using a mouse model of transverse aortic constriction (TAC). TAC led to a robust induction, whereas endothelial-specific depletion of SET1 led to a reduction of endothelin-1 mRNA and protein expression in mice ( Figure 7K ). SET1 silencing also attenuated pathological hypertrophy as a result of the TAC procedure in mice as measured by heart weight versus body weight or heart weight corrected by tibia length (Figure 7L 
Discussion
Epigenetic regulation of gene expression contributes to the pathogenesis of a range of human diseases. 22 Evidence is mounting that in stressed vascular endothelium, the epigenetic machinery can actively regulate transcription to modify endothelial function tailoring to the inputs by various pathological cues. [12] [13] [14] 23, 24 By means of paracrine and endocrine, these stress signals can be relayed from the endothelium to other parts of the cardiovascular system (eg, the heart) to trigger detrimental changes. In this report, we detail an epigenetically regulated pathway wherein the histone H3K4 methyltransferase SET1 activates endothelin-1 transcription in endothelial cells and contributes to the pathogenesis of cardiac hypertrophy in response to chronic Ang II treatment ( Figure 7M) .
Previously, it has been demonstrated that SET1 expression levels or activities are responsive to many different stress signals, including inflammation, 25 ischemia, 26 infection, 27 and nutrition surplus/deprivation. 28, 29 Here, we show that SET1 expression and SET1 binding on the endothelin-1 promoter can be upregulated in cultured endothelial cells and in the lungs in mice. More importantly, augmented expression and activity of SET1 by Ang II parallel the accumulation of H3K4Me3 on the endothelin-1 promoter and consequently endothelin-1 transactivation. Conversely, knockdown of SET1 both in vitro and in vivo erases H3K4Me3 from the endothelin-1 promoter and dampens endothelin-1 transactivation by Ang II. Thus, our data lend further support to the notion that SET1 might be a stress protein that can sense intrinsic and extrinsic signals and then program cellular response. These data also suggest that the ability of SET1 to regulate transcription and by extension cellular function is largely dictated by its enzyme activity of trimethylating H3K4 on gene promoters, alluding to the possibility that small-molecule SET1 inhibitors may serve as a powerful tool to modulate SET1-dependent gene expression and therefore alter cellular phenotype under stress conditions.
Interactions with sequence-specific transcription factors are a prerequisite for epigenetic proteins to be brought down on target promoters to participate in transcriptional regulation. 20 We have discovered in the present study a potential SET1-AP-1 complex responsible for endothelin-1 transactivation by Ang II. AP-1 is a universally expressed transcription factor known to exert a wide range of effects on the vasculature. 30 Several independent investigations have suggested that AP-1 may enlist the help of epigenetic factors, such as CREB binding protein, 31 PCAF (p300/CBP associated factor), 32 and Brahma-related gene 1, 33 to activate transcription. The finding that AP-1 may rely on SET1-dependent H3K4 methylation to activate endothelin-1 transcription reinforces the assertion that epigenetic factors play essential roles in transcriptional regulation. An intriguing question still remains on the SET1-AP-1 interplay: Is the dialogue between SET1 and AP-1 direct? Tang et al 34 have recently revealed a molecular pathway in which p300-mediated histone acetylation facilitates the recruitment of SET1 and contributes to the transcription of p53 genes. Our data indicate that histone acetylation and histone trimethylation occur simultaneously on the endothelin-1 promoter with similar kinetics after Ang II treatment (Figure 1 ), indicating that these two types of histone modifications are likely coupled. Crosstalk between different histone modifications helps shape the chromatin structure that potentially influences the binding of sequence-specific transcription factors and outcomes of transcriptional events. 34 Additional studies should focus on dissecting the interactions between SET1 and other epigenetic factors on the endothelin-1 promoter and determining whether these interactions could reciprocally affect the kinetics of AP-1 binding.
Vascular endothelium-derived endothelin-1 promotes cardiac hypertrophy and fibrosis. 10, 35 Using in vitro culture of cardiomyocyte and an animal model of Ang II-induced pathological hypertrophy, we confirm that SET1-dependent synthesis of endothelin-1 in endothelial cells contributes to the activation of a prohypertrophic and profibrogenic program in the heart in 2 different animal models. SET1 deficiency alleviated chronic infusion model-induced hypertrophy (Figure 7) . It also normalized the phenotype of mice in a TAC model ( Figure IV in the online-only Data Supplement). Mechanic stretch, as in the case of a TAC procedure, could activate the renin-angiotensin system thus stimulating the expression or activity of SET1 in endothelial cells. Alternatively, mechanic stretch, via a separate mechanism, could directly activate SET1 in endothelial cells independent of Ang II release. Of note, SET1 depletion did not affect blood pressure ( Figure  IIIE in the online-only Data Supplement). Nor did it ameliorate endothelial barrier leakage ( Figure IIIF in the online-only Data Supplement), indicating that SET1 might play a limited, rather than global, role in modulating endothelial function.
Clearly, transcriptomic comparison of SET1-null cell versus normal cell would be a new perspective in defining the role of SET1 in endothelial cells.
The evidence presented here, however, does not take into account the role of SET1 in other types of cells that may also contribute to cardiac hypertrophy and fibrosis. For instance, it has been shown that SET1 in macrophages is involved in the production of proinflammatory mediators, 25 another indication that suppressing SET1 activity might confer beneficial effects because inflammation tends to exacerbate cardiac hypertrophy. 36 Although these data collectively point to the potential of SET1 as a druggable target in the intervention of dilative cardiomyopathy, it is noteworthy that SET1 is necessary for maintaining the differentiation capability of stem cells. 37 Therefore, any attempt to limit SET1 activity to achieve a protective effect in preventing Ang II-induced pathological hypertrophy and fibrosis should be balanced against the potential caveat of diminishing cardiac stem cell differentiation. 38 In addition, SET1 expression can be found in a number of different cell types in the cardiovascular system including smooth muscle cell, fibroblast cell, epithelial cell, and cardiomyocyte ( Figure IIIB in the online-only Data Supplement). The cell-autonomous role for SET1 in these different cells remains unelucidated at this point rendering the outcome of targeting SET1 in vivo to achieve certain clinical outcomes equivocal. Additional studies using tissuespecific SET1 knockout models in combination with highthroughput gene profiling in different cell types deficient in SET1 would provide a more clear rationale in targeting SET for clinical purposes.
In summary, we present evidence to support a role for endothelial histone methyltransferase SET1 in promoting Ang II-induced pathological hypertrophy through endothelin-1 transactivation. Data mining of studies on the epigenetic regulation of carcinogenesis and metabolism has provided invaluable insights for human diseases. [39] [40] [41] A follow-up study should compare the binding patterns of SET1 and gene expression patterns in stressed endothelial cells on a genomewide scale. Once the role of SET1 in endothelial function is certified, a targeted therapy that aims at limiting the expression or activity of SET1 in endothelial cells may provide a new solution for the intervention of dilative cardiomyopathy. 
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